Concert Pharmaceuticals Inc.
This article was originally published in Start Up
Isolated from seawater, deuterium is a naturally occurring stable isotope of hydrogen that carries an additional neutron, and it is sometimes known as "heavy hydrogen." Concert Pharmaceuticals Inc. is using the properties of deuterium to create therapeutics based on existing drugs. Adding it to a compound can modify metabolism and create new applications and intellectual property, which Concert feels will enable it to develop highly differentiated medicines more quickly and at lower risk of failure. The company's lead candidate, the HIV protease inhibitor CTP-518, is a deuterium-modified version of Bristol-Myers Squibb's atazanavir.
You may also be interested in...
Privately held biotech hopes proof-of-concept data will attract a development partner for CTP-499 against CKD.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target the GI Tract," features profiles of Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences. Plus these Start-Ups Across Health Care: Advanced Cardiac Therapeutics, Concert Pharmaceuticals, ImThera Medical, On-Q-ity and Telormedix.
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty